Altered gamma delta T cell-keratinocyte interplay in the skin of diabetic mice

描述（由申请人提供）：糖尿病足溃疡是1型和2型糖尿病的常见并发症。迫切需要研究糖尿病如何影响上皮组织（如皮肤）的细胞-细胞相互作用，这些组织非常容易受到损伤。小鼠皮肤34 T细胞，也被称为树突状表皮T细胞（DETC），在皮肤稳态和伤口修复中发挥作用。激活的角质形成细胞和响应的DETC之间复杂的串扰是由受体表达和生长因子产生介导的。我们的长期目标是确定糖尿病如何对免疫系统产生负面影响，特别关注上皮T细胞群。本应用将研究2型糖尿病如何改变DETC的生存和功能，以及是否可以通过治疗逆转。目前的假设是，胰岛素抵抗性角质形成细胞长期刺激DETC，导致DETC凋亡并最终失能。这一假设是基于初步结果，该结果表明糖尿病皮肤中DETC和角质形成细胞之间的正常串扰发生了改变。本文提出了以下具体目标：(1)确定2型糖尿病小鼠皮肤中DETC减少的原因；(2)确定角化细胞-DETC串导对糖尿病小鼠DETC功能障碍的贡献；(3)恢复糖尿病小鼠DETC的数量和功能。一旦我们确定糖尿病小鼠皮肤中DETC是如何被抑制的，我们可能能够恢复激活并利用它们的伤口愈合潜力。这些具体目标将通过检查糖尿病皮肤中DETC数量如何下降以及剩余DETC是否在功能上无反应或无反应来检验。能量会影响DETC在正常体内平衡和伤口修复过程中增殖和分泌因子的能力。在2型糖尿病期间，将检测DETC和角化细胞之间的串扰，以确定角化细胞是否在DETC的抑制中发挥作用。最后，我们将采用两种方法来恢复糖尿病小鼠正常的DETC激活。首先，通过IL-2细胞因子治疗小鼠来恢复DETC的激活。第二种方法涉及改善胰岛素反应性，使角质形成细胞正常化，这可能间接恢复DETC功能。确定2型糖尿病对T细胞-上皮细胞相互作用的影响将大大提高我们对这种情况如何导致免疫功能障碍的认识。这将导致新策略的发展，以促进伤口修复和其他并发症的糖尿病。

DESCRIPTION (provided by applicant): Diabetic foot ulcerations are a debilitating complication common to type 1 and 2 diabetes. There is a critical need for studies that identify how diabetes affects cell-cell interactions in epithelial tissues such as the skin, which are very susceptible to damage. Murine skin 34 T cells, also known as dendritic epidermal T cells (DETC), play roles in skin homeostasis and wound repair. The complex cross-talk between the activating keratinocytes and the responding DETC is mediated by receptor expression and growth factor production. Our long-term goal is to determine how diabetes negatively impacts the immune system, with a special focus on epithelial T cell populations. This application will examine how type 2 diabetes alters the survival and function of DETC and whether this can be reversed therapeutically. The working hypothesis is that DETC are chronically stimulated by insulin resistant keratinocytes rendering the DETC apoptotic and eventually anergic. This hypothesis is based on preliminary results, which show that the normal cross-talk between DETC and keratinocytes is altered in diabetic skin. The following specific aims are proposed: (1) determine why DETC are diminished in the skin of mice with type 2 diabetes, (2) identify the contribution of keratinocyte-DETC cross-talk to DETC dysfunction in diabetic mice, and (3) restore DETC numbers and function in diabetic mice. Once we identify how DETC are suppressed in diabetic mouse skin we may be able to restore activation and exploit their wound healing potential. These specific aims will be tested by examining how DETC numbers decline in diabetic skin and whether the remaining DETC are rendered functionally unresponsive or anergic. Anergy would affect the ability of DETC to proliferate and secrete factors during normal homeostasis and wound repair. Cross-talk between DETC and keratinocytes will be examined during type 2 diabetes to identify whether keratinocytes play a role in the suppression of DETC. Finally, two approaches will be taken to restore normal DETC activation in diabetic mice. First, the DETC will be targeted by treating mice with IL-2 cytokine therapy to restore DETC activation. The second approach involves improving insulin responsiveness to allow the keratinocytes to normalize, which may indirectly restore DETC function. Defining the impact of type 2 diabetes on T cell- epithelial cell interactions will greatly advance our knowledge of how this condition may lead to immune dysfunction. This will lead to the development of novel strategies to promote wound repair and other complications of diabetes.